Cyclandelate - CAS 456-59-7
Catalog number: 456-59-7
Category: Inhibitor
Please be kindly noted products are not for therapeutic use. We do not sell to patients.
Molecular Formula:
C17H24O3
Molecular Weight:
276.37
COA:
Inquire
Targets:
Others
Description:
Cyclandelate is an effective inhibitor of rat hepatic acycloenzyme A: cholesterol acyltransferase (ACAT) with IC50 of 80 μM.
Purity:
>98%
Synonyms:
BS 572; BS572; BS-572
MSDS:
Inquire
InChIKey:
WZHCOOQXZCIUNC-UHFFFAOYSA-N
InChI:
InChI=1S/C17H24O3/c1-12-9-14(11-17(2,3)10-12)20-16(19)15(18)13-7-5-4-6-8-13/h4-8,12,14-15,18H,9-11H2,1-3H3
Canonical SMILES:
CC1CC(CC(C1)(C)C)OC(=O)C(C2=CC=CC=C2)O
1.Cyclandelate in the prophylaxis of migraine: a placebo-controlled study.
Diener HC1, Krupp P, Schmitt T, Steitz G, Milde K, Freytag S. Cephalalgia. 2001 Feb;21(1):66-70.
The prophylactic action of cyclandelate was investigated in a multicentre, randomized, placebo-controlled, parallel group study. A 4-week baseline period was followed by a 4-week placebo phase and a 16-week treatment period with either 1600 mg cyclandelate or placebo. Patients (n = 251) with two to six migraine attacks/month were randomized. Neither the primary study endpoint (reduction of migraine days from baseline to the last 28 days) nor most of the secondary endpoints (reduction in the number of migraine attacks, severity or duration of attacks, frequency of autonomic disturbances, medication for treatment of attacks) showed a difference between cyclandelate and placebo. Cyclandelate, however, was superior to placebo in a global impression of efficacy rated by the patients and the treating physicians. Both treatments were well tolerated. In conclusion, cyclandelate was not superior to placebo in the prophylaxis of migraine with regard to parameters usually used in migraine prophylaxis trials.
2.Differences in endogenous esterification and retention in the rat trachea between budesonide and ciclesonide active metabolite.
Lexmüller K1, Gullstrand H, Axelsson BO, Sjölin P, Korn SH, Silberstein DS, Miller-Larsson A. Drug Metab Dispos. 2007 Oct;35(10):1788-96. Epub 2007 Jul 12.
The airway retention of inhaled glucocorticosteroids (GCs) depends largely on their lipophilicity. Inhaled budesonide (BUD) becomes highly lipophilic reversibly by the formation of esters acting as a reservoir of active BUD. Ciclesonide (CIC) was also reported to form esters after hydrolysis to active metabolite (CIC-AM). We have investigated lipophilicity and airway retention of BUD, CIC/CIC-AM, fluticasone propionate (FP), and mometasone furoate (MF), and compared esterification of BUD and CIC-AM and its contribution to GC airway retention. Rat tracheas were preincubated with the esterification inhibitor cyclandelate or vehicle. A (3)H-GC ( approximately 10(-7) M: BUD, CIC, CIC-AM, FP, MF) was added for 20 min. After incubation, one half of the trachea was used for analysis of GC uptake and the other to analyze GC release during 3 h in drug-free medium. GC species in trachea halves were analyzed by radiochromatography. At 20 min, the uptake of BUD was similar to that of CIC/CIC-AM; however, the BUD-ester pool was 9-fold greater (p < 0.
3.Cyclandelate in the treatment of patients with mild to moderate primary degenerative dementia of the Alzheimer type or vascular dementia: experience from a placebo controlled multi-center study.
Weyer G1, Eul A, Milde K, Wierich W, Herrmann WM. Pharmacopsychiatry. 2000 May;33(3):89-97.
A 24-week, double-blind, multi-center, randomised parallel group study compared the efficacy and safety of 800 mg bid cyclandelate with placebo in patients with mild to moderate dementia of primary degenerative or vascular origin. A total of 196 patients entered the study, 147 patients completed treatment in adherence with the protocol. Primary outcome measures were the cognitive score of the Alzheimer's Disease Assessment Scale (ADAS-Cog), the subscale Instrumental Activities of Daily Living of the Nurses' Observation Scale for Geriatric Patients (NOSGER-IADL) and the Clinical Global Impressions of Change (CGI-C). Safety assessments included adverse events, vital signs, ECG and clinical laboratory parameters. The primary efficacy results based on a multi-level responder analysis including ADAS-Cog, NOSGER-IADL and CGI-C failed to demonstrate statistical superiority of cyclandelate in comparison to placebo. The direction of changes favored cyclandelate in each of the variables, but the differences to placebo were small and varied considerably between patients and centers.
4.Inhibition of purified pig and human liver retinyl ester hydrolase by pharmacologic agents.
Schindler R1. Lipids. 2001 May;36(5):543-8.
Identification of inhibitors of retinyl ester hydrolase (REH) would help to elucidate its role in vitamin A metabolism in vivo. By using standard incubation conditions, the effects of 215 drugs as potential inhibitors of purified pig and human liver REH when acting on micellar substrate retinyl palmitate were evaluated at 16.7, 167, and 1670 microM. Out of the compounds tested, 103 were inhibitors of the pig liver enzyme. The most potent compounds, in order of decreasing activity, were chloral hydrate, lovastatin, phytomenadione, alimemazine, physostigmine, thioridazine, phenoxybenzamine, probucol, cinnarizine, cyclandelate, amiodarone, flupenthixol, and naftidrofuryl; this order is roughly similar to that of their inhibition of human liver REH. Of the 10 tricyclic ring-containing drugs tested, alimemazine was the most potent enzyme inhibitor. The concentrations necessary for 50% enzyme inhibition ranged from <2.6 up to >540 microM.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related Products


CAS 93565-01-6 MDL 72527

MDL 72527
(CAS: 93565-01-6)

MDL 72527 is a polyamine oxidase inhibitor. It can block the production of H2O2 and increase the cells survival. MDL 72527 shows anticancer and neuroprotective ...

CAS 315704-66-6 PTC-209

PTC-209
(CAS: 315704-66-6)

PTC-209 is a potent BMI-1 inhibitor with potential anticancer activity. PTC-209 inhibits endogenous BMI-1 expression in human colorectal HCT116 and human fibros...

CAS 145961-79-1 ACAT-IN-1 cis isomer

ACAT-IN-1 cis isomer
(CAS: 145961-79-1)

A potent ACAT inhibitor (IC50= 100 nM)

PD-138312
(CAS: 107334-06-5)

PD-138312 is a novel broad-spectrum 7-pyrrolidinyl fluoronaphthyridines with a difluorophenyl substitution or a cyclopropyl at the 1 positions, respectively. It...

CAS 110314-48-2 Adolezesin

Adolezesin
(CAS: 110314-48-2)

Adozelesin is an experimental antitumor drug of the duocarmycin class. It is the first of a class of DNA-sequence-selective alkylating agents. It binds to and a...

CAS 478336-92-4 ISO-1

ISO-1
(CAS: 478336-92-4)

ISO-1 is an inhibitor of the dopachrome tautomerase activity of MIF. It blocks the activation of NF-κB and TNF-α secretion from LPS-treated macrophages and impr...

CAS 83-88-5 Riboflavin

Riboflavin
(CAS: 83-88-5)

Riboflavin, also known as vitamin B2, is an easily absorbed micronutrient with a key role in maintaining health in humans and other animals.<br/>Vitamin supplem...

CAS 7195-27-9 Mefruside

Mefruside
(CAS: 7195-27-9)

Mefruside is a Na+/Cl- symport under the development of Bayer A.G. It is a diuretic that using for the treatment of edema and hypertension

Chemical Structure

CAS 456-59-7 Cyclandelate

Quick Inquiry

Verification code

Featured Items